Perspectives Across the PharPoint Team
Clinical Operations
- Relationship building: Rare disease research requires a high level of trust and patient centricity. It is hugely important for investigators to build a relationship with patients and caregivers.
- Logistical challenges: Many rare disease studies involve pediatric populations, which adds complexity. This includes logistical challenges like travel and caregiver time away from work. One way teams can help reduce this burden is through partnership with patient concierge services that can manage travel logistics for patients and caregivers.
- Recruitment: Recruiting eligible patients is typically difficult due to small population sizes. To meet enrollment goals, sponsors may pursure potential recruitment strategies including searching global registries to identify potential patients, collaborating with patient groups who list clinical trials on their website, participating in community events that support rare disease awareness, and opening additional study sites.
- Collaboration: Close collaboration with investigators, study sites, and key opinion leaders is critical. These experts might have rare firsthand experience supporting similar studies and can provide invaluable insight that informs trial strategy.
Data Management
- Indication-specific assessments: Rare disease trials often include indication-specific assessments – e.g., the Unified Huntington’s Disease Rating Scale (UHDRS) for Huntington’s Disease. These assessments can be highly intricate, requiring extensive domain knowledge.
- Pediatric challenges: Pediatric patient populations have unique considerations. For example, consider the type of drug administration – can pediatric patients swallow capsules? Could the investigative product instead be sprinkled over food, or poured directly in the mouth? If drug administration is not agreeable to the patient population, recruitment will be challenging.
- Study globalization: Enrollment is one of the biggest challenges in rare disease trials. To meet enrollment goals, trials often have to expand to include multiple countries.
According to Biostatistics:
- Conversations with regulatory agencies: Often, regulatory agencies don’t have clear guidelines for each specific rare disease. Defining appropriate efficacy endpoints can require several conversations with agencies.
- Adhoc analyses: Regulatory agencies and sponsors alike often want to get as much information out of the data as possible. This results in intensive ad hoc analysis schedules that explore every potential insight.
- Small sample sizes: Small sample sizes make for challenging analyses.
According to Quality Assurance:
- The importance of quality: The impact of poor quality is amplified for smaller populations, where every deviation, visit, and data point carries more weight.
- Patient privacy: Maintaining patient privacy under regulations such as HIPAA and GDPR can be especially challenging. In ultra-rare disease studies, even minimal data points such as age and city can inadvertently identify patients, requiring exceptional diligence.
- A strong quality culture: Rare disease studies foster a strong quality culture. Leaders are often deeply motivated by the patient experience and communicate that purpose clearly to their teams. This shared commitment attracts individuals who believe in the mission and want to make a meaningful difference. Across conversations, there is continuous acknowledgement of the patient perspective.
The Most Important Perspective
The most critical perspective in rare disease research is that of the patients and caregivers whose lives are directly impacted.
This theme emerged consistently across all responses. Beyond operational lessons learned, team members spoke with passion and personal connection. With 1 in 10 Americans affected by a rare disease, many have friends or family members affected by diseases without available treatments.
One data manager reflected on her experience with Menkes disease, a rare genetic disorder that disrupts copper transport in the body. As a child, they witnessed a cousin lose his life to the disease at a time when no treatment existed. Years later, another family member’s child was affected and also passed away. She was thrilled to see, in January 2026, FDA announce the first approved treatment for children with Menkes disease. While a drug for a rare disorder like Menkes disease may never become a blockbuster product, the value is immeasurable to the families it serves.
Team members emphasized that although rare disease trials can be perceived as having limited overall impact due to small populations, for each patient and caregiver involved, these studies can be a beacon of hope.
Finally, there was a shared sense of gratitude for the opportunity to support rare disease research.
About PharPoint
PharPoint Research is a collaborative contract research organization (CRO) that helps sponsors of all sizes meet study goals.
To learn more about how PharPoint’s experience supporting rare disease clinical trials, reach out to our business development team.
